Verona Pharma Plc Stock Today

VRNA Stock  USD 22.95  0.37  1.64%   

Performance

12 of 100

 
Weak
 
Strong
Good

Odds Of Distress

Less than 16

 
High
 
Low
Low
Verona Pharma is trading at 22.95 as of the 21st of July 2024, a 1.64% increase since the beginning of the trading day. The stock's open price was 22.58. Verona Pharma has less than a 16 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. Equity ratings for Verona Pharma PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of June 2024 and ending today, the 21st of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
27th of April 2017
Category
Healthcare
Classification
Health Care
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom. The company has 81.08 M outstanding shares of which 8.64 M shares are at this time shorted by private and institutional investors with about 4.9 trading days to cover. More on Verona Pharma PLC

Moving against Verona Stock

  0.57ZURA Zura Bio LimitedPairCorr
  0.54ENVB Enveric BiosciencesPairCorr
  0.51OCEA Ocean BiomedicalPairCorr
  0.49ELEV Elevation OncologyPairCorr
  0.35XFOR X4 PharmaceuticalsPairCorr
  0.33CGC Canopy Growth CorpPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Verona Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentDavid PharmD
Thematic IdeaPharmaceutical Products (View all Themes)
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Jakarta Stock Exchange, Pharmaceutical Products, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00150.0016
Notably Down
Pretty Stable
Total Current Liabilities7.7 M8.7 M
Fairly Down
Slightly volatile
Total Assets323.5 M308.1 M
Sufficiently Up
Slightly volatile
Total Current Assets304.2 M289.7 M
Sufficiently Up
Slightly volatile
Debt Levels
Verona Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Verona Pharma's financial leverage. It provides some insight into what part of Verona Pharma's total assets is financed by creditors.
Liquidity
Verona Pharma PLC currently holds 51.33 M in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Verona Pharma PLC has a current ratio of 3.5, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Verona Pharma's use of debt, we should always consider it together with its cash and equity.

Change In Cash

46.14 Million
Verona Pharma PLC (VRNA) is traded on NASDAQ Exchange in USA. It is located in 3 More London Riverside, London, United Kingdom, SE1 2RE and employs 79 people. Verona Pharma is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.86 B. Verona Pharma PLC conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 81.08 M outstanding shares of which 8.64 M shares are at this time shorted by private and institutional investors with about 4.9 trading days to cover. Verona Pharma PLC currently holds about 111.51 M in cash with (50.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83.
Check Verona Pharma Probability Of Bankruptcy
Ownership Allocation
Verona Pharma PLC shows a total of 81.08 Million outstanding shares. The majority of Verona Pharma PLC outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Verona Pharma to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Verona Pharma PLC. Please pay attention to any change in the institutional holdings of Verona Pharma PLC as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Verona Ownership Details

Verona Stock Institutional Holders

InstituionRecorded OnShares
Hhg Plc2024-03-31
M
Maverick Capital Ltd2024-03-31
1.8 M
Fmr Inc2024-03-31
1.7 M
Jennison Associates Llc2024-03-31
1.6 M
Caligan Partners Lp2024-03-31
1.3 M
Bellevue Group Ag2024-03-31
1.1 M
Aisling Capital Management Lp2024-03-31
1.1 M
Hood River Capital Management Llc2024-03-31
987.8 K
First Turn Management Llc2024-03-31
973.1 K
Ra Capital Management, Llc2024-03-31
6.3 M
Nea Management Company, Llc2024-03-31
5.1 M
View Verona Pharma Diagnostics

Verona Pharma Historical Income Statement

At present, Verona Pharma's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 45.9 M, whereas Operating Income is projected to grow to (64.4 M). View More Fundamentals

Verona Stock Against Markets

Verona Pharma Corporate Management

Caroline DiazSenior AffairsProfile
LCSW BAG CounselProfile
Matthew CasbonMarketing SalesProfile
Peter SpargoSenior ControlsProfile
Kathleen MDChief OfficerProfile
B ASIAGeneral CounselProfile

Additional Information and Resources on Investing in Verona Stock

When determining whether Verona Pharma PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verona Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verona Pharma Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verona Pharma Plc Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.80)
Revenue Per Share
0.006
Return On Assets
(0.15)
Return On Equity
(0.25)
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.